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 Abstract 
Background: Some patients with chronic obstructive pulmonary disease (COPD) have asthma-like 
features. However, there have been few reports on the structural lung abnormalities found in this patient 
population. Multi-detector computed tomography (MDCT) can detect emphysematous low-attenuation 
areas (LAA) within the lung, airway thickness (wall area percentage, WA%), and the loss of pulmonary 
vasculature as the percentage of small pulmonary vessels with cross-sectional area (CSA) less than 5 
mm
2
 (%CSA<5). We analyzed differences in structural lung changes over time between patients with 
COPD and those with COPD with asthma-like features using these CT parameters. 
Material and Methods: We performed pulmonary function tests (PFTs), MDCT, and a COPD 
assessment test (CAT) in 50 patients with COPD and 29 patients with COPD with asthma-like features 
at the time of enrollment and two years later. We analyzed changes in clinical parameters and CT 
indices over time and evaluated differences in structural changes between groups. 
Results: The CAT score and FEV1 did not significantly change during the follow-up period in either 
group. Emphysematous LAA regions significantly increased in both groups. The %CSA<5 showed a 
small but significant increase in COPD patients, but a significant decrease in patients with COPD with 
asthma-like features. The WA% at the distal bronchi was significantly decreased in COPD, but did not 
significantly change in COPD with asthma -like features. 
Conclusion: Emphysematous LAA increased in patients with COPD with and without asthma-like 
features. The %CSA<5 and WA% at the distal bronchi did not change in parallel with LAA. 
Furthermore, changes in %CSA<5 were significantly different between patients with COPD and those 
with COPD with asthma-like features. Patients with COPD with asthma-like features may have 
different longitudinal structural changes than those seen in COPD patients. 
 
  
 Background 
Chronic obstructive pulmonary disease (COPD), a common disease that is increasing in 
prevalence, is characterized by persistent respiratory symptoms and chronic airflow limitation [1]. 
Worldwide, COPD is the third leading cause of death, and mortality continues to rise [2]. The chronic 
airflow limitation in COPD is caused by a mixture of small airway disease and parenchymal destruction, 
which leads to multiple COPD phenotypes. For example, the classical phenotype is emphysema/chronic 
bronchitis, and other phenotypes are frequent-exacerbator/non-exacerbator [3, 4]. Recently, “asthma- 
COPD overlap” (ACO) has been recognized in clinical practice. A joint project of the Global Initiative 
for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published 
a consensus on ACO [5]. The prevalence of ACO has been reported to be between 13% and 55% [6]. It 
has not been defined definitively, and previous studies have used multiple different diagnostic criteria. 
The asthmatic components for the diagnosis of ACO include history of asthma; asthma-like symptoms, 
positive bronchodilator test, blood eosinophilia, high total IgE, and/or atopy etc. [6-8]. GINA/GOLD 
applies a stepwise approach for the diagnosis of ACO, in which each characteristic of COPD and 
asthma are assessed. However, some patients with COPD have asthma-like features [9], even if they are 
not diagnosed as ACO. COPD with asthma-like features is a clinical phenotype of COPD and this 
phenotype is associated to individualized treatment [9-11]. 
Recently, multi-detector computed tomography (MDCT) has been used to evaluate structural 
changes in the lung. The loss of lung tissue associated with emphysema is detected as low-attenuation 
areas (LAA) on CT scans [12]. LAA percentage (LAA%) in patients with COPD is higher than in 
normal subjects [13], and correlates with COPD mortality independently of pulmonary function tests 
[14]. Airway wall thickening can also be measured using CT. Nakano et al. found that wall thickening 
in the apical bronchus of the right upper lobe correlated significantly with FEV1 in patients with COPD 
[15]. The inner luminal area (Ai) and the wall thickness (wall area percentage, WA%) were measured at 
the third- to the sixth-generation airways. These indices correlated significantly with airflow limitation, 
and such correlations were more closely related to the distal than the proximal airways [16]. Moreover, 
chronic respiratory symptoms were positively associated with WA% in airways with a luminal diameter 
between 5 and 10 mm [17]. Recently, several studies have used a novel CT marker to evaluate the area 
of small pulmonary vessels, the percentage of small pulmonary vessels (%CSA). The %CSA<5 reflects 
 pulmonary vascular alteration and correlates with airflow limitation, the extent of emphysema, and 
pulmonary hypertension in patients with COPD [18, 19]. 
Although there are many longitudinal studies on health status and lung function in COPD [20],
 
longitudinal structural changes in COPD with asthma-like features have not been fully investigated. 
Several studies have been performed in patients with emphysema [21, 22], but there are few reports on 
changes in airway [23] or vascular remodeling [24]. The structural characteristics of ACO and COPD 
are different. Hardin et al. reported that patients with ACO had less emphysema and greater airway wall 
thickness compared to patients with COPD [25]. We previously examined longitudinal structural 
changes in COPD patients and found that WA% at the distal bronchi and %CSA<5 did not change in 
parallel with LAA [26]. However, differences in longitudinal structural changes between the patients 
with COPD versus those with COPD with asthma-like features have not been fully elucidated. 
The recognition of COPD with asthma-like features by the assessment of their structural 
characteristics may provide essential information for individualized management of patients 
with COPD. The present study aimed to investigate the longitudinal structural changes in 
patients with COPD with asthma-like features using MDCT. Such changes include changes in 
pulmonary emphysema, airway disease, and pulmonary vascular alteration. This study also 
aimed to evaluate the differences in structural abnormalities between COPD patients and 
patients with COPD with asthma-like features. 
 
Materials and methods 
Subjects 
This prospective observational study enrolled 137 patients who presented to Chiba University 
Hospital from June 2010 to August 2016 for management of COPD. Patients were excluded if they had 
abnormal lung parenchymal lesions other than emphysematous change. At enrollment, 10 patients were 
excluded for the following reasons: 4 interstitial pneumonia, 1 infectious pneumonia, 1 old pulmonary 
tuberculosis, and 4 lung cancer or nodules. At the follow up period, 15 patients were excluded: 6 
interstitial pneumonia, 2 infectious pneumonia, 3 lung cancer or nodules, 2 cardiac failure, and 2 pleural 
effusion. Finally, 50 patients with COPD and 29 patients with COPD with asthma-like features were 
enrolled in the study (Fig 1). The diagnosis of COPD was based on chronic respiratory symptoms, with 
 smoking history, physical examination and results of spirometry according to the American Thoracic 
Society (ATS) and European Respiratory Society (ERS) recommendations [27]. Pulmonary function 
tests (PFTs) were performed with a Fudac-60 (Fukuda Denshi; Tokyo, Japan). Spirometric 
measurements included forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1), 
which were expressed as their predicted values based on the Japanese Respiratory Society (JRS) 
guidelines [28]. 
In this study, patients with COPD who experienced asthma symptoms (episodes of 
breathlessness, wheezing, cough, and chest tightness that were worse at night or in the early morning), 
bronchodilator reversibility (improvement greater than or equal to 200ml and 12% increase in FEV1 
compared to pre-bronchodilator data), blood eosinophils >5% or 300/ml, high levels of serum IgE, 
and/or history of allergic rhinitis were diagnosed with COPD with asthma-like features, in accordance 
with GINA and GOLD guidelines [5]. 
Patients underwent a COPD assessment test (CAT), PFTs and MDCT at the time of enrollment 
and two years later. Exacerbations were defined as a deterioration of respiratory symptoms that required 
antibiotics, systemic steroids and/or hospital admission [22]. 
The Ethics Committee of the Chiba University School of Medicine approved the study protocol 
(approval number: 857). Written informed consent was obtained from all study participants. 
 
Fig 1.  Flow chart of the study participants 
 
MDCT scanning 
All patients were scanned with a 64-MDCT scanner (Aquillion ONE, Toshiba Medical 
Systems; Tokyo, Japan) from the thoracic inlet to the diaphragm while at full inspiration. None received 
contrast medium. The scan was carried out with the following settings: 0.5-mm collimation; 120kV; 
auto-exposure control; gantry rotation time of 0.5 seconds; and beam pitch of 0.83. All images were 
reconstructed using standard reconstruction algorithms with a slice thickness of 0.5 mm and a 
reconstruction interval of 0.5 mm. The voxel size was 0.63×0.63×0.5 mm. 
 
MDCT measurements 
 For the measurements of LAA and CSA, we selected three CT slices, which were taken at 1 cm 
above the upper margin of the aortic arch (upper lung fields), 1 cm below the carina (middle lung fields), 
and 1 cm below the right inferior pulmonary vein (lower lung fields) [18]. These CT images were 
analyzed using ImageJ software, Version 1.44 (imagej.nih.gov/ij/download/).  
LAA measurements were conducted as follows: The threshold technique for the total lung area 
(TLA) was adopted between -500 and -1024 Hounsfield units (HU). Since LAA was detected with an 
attenuation of -950 HU, images were converted into binary images with a window level of -950 HU. 
The range of circularity was set from 0 to infinity. With these settings, the LAA was automatically 
calculated. The LAAs of each lung field were summed, and the average of these values was determined. 
CSA measurements were conducted as follows:
 
The threshold technique for the total lung field 
was adopted between -500 and -1024 HU. Segmented images were converted into binary images with a 
window level of -720 HU. The range of circularity was set from 0.9 to 1.0 using the "analyze particles" 
function of the ImageJ software. With these settings, the CSA was measured separately by the size of 
each vessel (less than 5 mm
2
; CSA<5). The CSAs of each lung field were summed, and the average of 
these values was determined. The percentage of CSA<5 (%CSA<5), and LAA (%LAA) in the TLA 
were calculated. 
We used the free open-source software Airway Inspector (Brigham and Women’s Hospital) for 
the measurements of WA%. WA% measurements were conducted according to the method of 
Yamashiro et al. [29]. We identified the third and fifth generations of the B1 and B10 bronchi in the 
right lung. The measured point was peripherally next to the branching points in each generation. Ai and 
the outer area of the bronchus (Ao) were measured semiautomatically with the full-width at 
half-maximum method of the software. The WA% was defined with the equation WA% = 100 (Ao - Ai) 
/ Ao. The MDCT measurements were evaluated independently by two pulmonologists (RA and YM). 
All data were anonymized and the observers were blinded to other characteristics of the subjects when 
the imaging analyses were performed. 
 
Statistical analysis 
JMP 13.0 software was used for all statistical analyses (SAS Institute, Cary, NC), with the results 
expressed as mean (± SD) unless otherwise indicated. Comparisons of longitudinal changes in CT 
 parameters, PFTs, and CAT scores between enrollment and follow-up in each group were performed 
using the Wilcoxon signed-rank test. Comparisons were performed with a chi-square test for categorical 
variables. Differences in the data between the patients with COPD and COPD with asthma-like features 
were performed with the Mann-Whitney U test. For all statistical analyses, the level of significance was 
set at p <0.05. 
 
Results 
Patient characteristics 
The clinical characteristics of the patients are presented in Table 1. There were 50 patients with COPD 
(44 men and 6 women; mean age, 70.1 ± 6.9 years) and 29 patients with COPD with asthma-like 
features (23 men and 6 women; mean age, 67.9 ± 8.5 years). There were no differences between the two 
groups in age, sex, percentage of ex/current smokers, smoking history or body mass index. All of the 
patients with COPD with asthma-like features met the criteria for asthma symptoms, whereas 9 (31%) 
had bronchodilator reversibility, 17 (59%) had blood eosinophilia, 13 (45%) had high levels of serum 
IgE, and 2 (7%) had a history of allergic rhinitis. The number of patients in each GOLD stage were as 
follows: COPD group: stage I, n = 13 (26%); stage II, n = 27 (54%); stage III, n = 7 (14%); stage IV, n 
= 3 (6%); COPD with asthma- like features group: stage I, n = 3 (10.3%); stage II, n = 12 (41.4%); 
stage III, n = 11 (38%); stage IV, n = 3 (10.3%). The COPD with asthma-like features group contained 
more patients with severe GOLD stage disease (P = 0.048), and the frequency of exacerbation tended to 
be higher in the group with COPD with asthma-like features (COPD vs asthma-like features: 1.4 ± 1.0 
vs 3.1 ± 3.8, P = 0.0617). Additionally, the number of patients who received COPD treatment at 
enrollment and two years later was higher in the COPD with asthma-like features group (COPD vs 
asthma-like features: at enrollment 30% vs 89.7%, P < 0.0001, 2 years later 64.0% vs 96.6%, P = 
0.0003). 
 
Table 1. Characteristics of patients with COPD with and without asthma-like features 
 
  
BMI, body mass index; LAMA, long-acting muscarinic antagonist; LABA, long-acting β-agonist; ICS, 
inhaled corticosteroids; SD, standard deviation; NS, not significant 
 
 
CAT score and PFTs 
The CAT score, FEV1, and FEV1%predicted did not significantly change during the follow-up 
period in either group (Tables 2 and 3). 
 COPD 
Mean (±SD) 
n = 50 
COPD with asthma-like 
features  
Mean (±SD) 
n = 29 
P value 
(between groups) 
Age (years) 70.1 ± 6.9 67.9 ± 8.5 NS 
Sex (male/female) 44 (88%) / 6 (12%) 23 (79.3%) / 6 (20.7%) NS 
Ex-smokers/Current smokers 40 (80%) / 10 (20%) 27 (93.1%) / 2 (6.9%) NS 
Smoking history (pack-years) 56.0 ± 30.7 57.8 ± 44.5 NS 
BMI (kg/m
2
) 23.8 ± 3.0 22.7 ± 3.4 NS 
GOLD classification 
(Ⅰ/Ⅱ/Ⅲ/Ⅳ) 
13 (26%) / 27 (54%) / 
7 (14%) / 3 (6%) 
3 (10.3%) / 12 (41.4%) / 
11 (38.0%) / 3 (10.3%) 
0.048 
Exacerbations (+/-) 12 (24%) / 38 (76%) 9 (31.0%) / 20 (69.0%) NS 
Exacerbations per 1 year 0.8 ± 0.5 1.6 ± 1.9 NS 
COPD Treatment (Yes/No)  
at enrollment 
15 (30%) / 35 (70%) 26 (89.7%) / 3 (10.3%) < 0.0001 
LAMA 15 (30%) 16 (55.2%)  
LABA 1 (2%) 8 (27.6%) 
ICS 0 (0%) 1 (3.4%) 
ICS/LABA 4 (8%) 14 (48.3%) 
LAMA/LABA 0 (0%) 2 (6.9%) 
COPD Treatment (Yes/No) 
after 2 years 
32 (64%) / 18 (36%) 28 (96.6%) / 1 (3.4%) 0.0003 
LAMA 27 (54%) 20 (69.0%)  
LABA 8 (16%) 6 (20.7%) 
ICS 0 (0%) 7 (24.1%) 
ICS/LABA 13 (26%) 14 (48.3%) 
LAMA/LABA 0 (0%) 3 (10.3%) 
  
Table 2. Longitudinal changes in CAT score, PFTs, and CT measurements  
CAT score, COPD assessment test score; PFTs, pulmonary function tests; FVC, forced vital capacity; 
FEV1, forced expiratory volume in 1 second; V50/V25, forced expiratory flow at 50% vital capacity 
and forced expiratory flow at 25% vital capacity; TLA, total lung area; LAA, low-attenuation area; 
CSA<5, the cross-sectional area of pulmonary vessels <5 mm
2
; WA%, wall area percentage; SD, 
standard deviation; NS, not significant 
 
Table 3. Annual changes in CAT score, PFTs, and CT measurements: Intra- and inter-group 
comparisons between patients with COPD with and without asthma-like features 
 
 COPD 
Baseline 
Mean (±SD) 
2-Year 
Follow-up 
Mean (±SD) 
P value 
(within 
group) 
COPD with 
asthma-like 
features 
Baseline 
Mean (±SD)  
2-Year 
Follow-up 
Mean (±SD) 
P value 
(within 
group) 
CAT score 8.7 ± 6.5 8.6 ± 7.1 NS 9.4 ± 7.0 10.6 ± 7.4 NS 
FVC (L) 3.15 ± 0.72 3.19 ± 0.77 NS 3.01 ± 0.91 2.96 ± 0.86 NS 
FEV1 (L) 1.83 ± 0.61 1.81 ± 0.62 NS 1.45 ± 0.55 1.41 ± 0.56 NS 
FEV1/FVC (%) 57.5 ± 11.8 55.9 ± 11.5 0.0381 48.2 ± 11.0 47.5 ± 11.7 NS 
FEV1% 
predicted (%) 
67.9 ± 19.8 69.0 ± 21.3 NS 53.6 ± 17.7 53.9 ± 19.3 NS 
V50/V25 3.7 ± 1.2 4.1 ± 1.6 0.0217 3.3 ± 1.3 3.3 ± 1.5 NS 
TLA (mm
2
) 22272 ± 3091 22131 ± 3277 NS 22841 ± 4620 22823 ± 4824 NS 
LAA (mm
2
) 1648 ± 2709 2144 ± 3100 < 0.0001 2787 ± 3606 3626 ± 4139 < 0.0001 
LAA% (%) 6.8 ± 10.4 8.8 ± 11.7 < 0.0001 10.8 ± 13.0 14.1 ± 14.6 < 0.0001 
CSA<5 (mm
2
) 157.0 ± 34.2 168.9 ± 39.7 0.0047 164.2 ± 33.4 147.7 ± 27.1 0.0034 
%CSA<5 (%) 0.72 ± 0.19 0.78 ± 0.21 0.0074 0.77 ± 0.22 0.70 ± 0.21 0.0148 
B1 WA%       
Third 72.5 ± 7.2 72.0 ± 6.4 NS 71.0 ± 6.6 70.9 ± 9.0 NS 
Fifth 83.9 ± 4.7 83.0 ± 4.6 NS 84.9 ± 4.1 83.6 ± 7.1 NS 
B10 WA%       
Third 71.4 ± 7.0 69.6 ± 6.7 NS 70.7 ± 7.5 71.1 ± 6.8 NS 
Fifth 83.8 ± 3.8 80.9 ± 6.2 0.0004 82.8 ± 4.8 82.5 ± 4.7 NS 
Mean WA%       
Third 72.2 ± 6.1 70.9 ± 4.8 NS 70.9 ± 5.6 71.2 ± 6.5 NS 
Fifth 83.9 ± 3.2 82.0 ± 4.6 0.0043 83.9 ± 3.5 83.2 ± 4.0 NS 
  
CAT score, COPD assessment test score; PFTs, pulmonary function tests; FVC, forced vital capacity; 
FEV1, forced expiratory volume in 1 second; LAA, low-attenuation area; CSA<5, cross-sectional area 
of pulmonary vessels <5 mm
2
; WA%, wall area percentage; NS, not significant. 
The data are expressed as mean ± standard deviation. 
The difference in CAT score was calculated by subtracting the value measured after 2 years from that 
measured at enrollment. 
The difference in FEV1 (L) was calculated by subtracting the value measured after 2 years from that 
measured at enrollment. 
The difference in FEV1% predicted (%) and the CT parameters (%) were calculated as follows: 
subtraction of the value measured after 2 years from that measured at enrollment, divided by the value 
at enrollment. 
 
CT parameters  
The CT parameters measured at enrollment and follow-up CT scans are shown in Table 2, 
while the annual changes in CT measurements are shown in Table 3. Fig 2 shows the changes in 
radiological parameters over two years of follow- up. There was no significant difference in all the CT 
parameters including LAA%, CSA<5, and WA% at enrollment between the two groups. LAA and 
LAA% significantly increased in both groups during the follow-up period (COPD: baseline vs two 
years later: 6.8 ± 10.4% vs 8.8 ± 11.7%, P < 0.0001. COPD with asthma-like features: baseline vs two 
years later: 10.8 ± 13.0% vs 14.1 ± 14.6%, P < 0.0001). TLA did not significantly change. The CSA<5 
and %CSA<5 slightly but significantly increased in the COPD group (baseline vs two years later: 0.72 
± 0.19% vs 0.78 ± 0.21%, P = 0.0074). In contrast, the CSA<5 and %CSA<5 significantly decreased in 
 COPD COPD with asthma-like features P value 
(between groups) Value P value 
(within group) 
Value P value 
(within group) 
CAT score -0.1 ± 3.0 NS 0.3 ± 1.8 NS NS 
FEV1 (L) -0.01 ± 0.11 NS -0.02 ± 0.08 NS NS 
FEV1% 
predicted (%) 
0.010 ± 0.086 NS -0.001 ± 0.054 NS NS 
LAA% (%) 0.83 ± 1.72 < 0.0001 0.40 ± 0.53 < 0.0001 NS 
%CSA<5 (%) 0.051 ± 0.104 0.0074 -0.035 ± 0.094 0.0148 0.0007 
Mean WA% (%)      
Third -0.007 ± 0.037 NS 0.002 ± 0.027 NS NS 
Fifth -0.011 ± 0.025 0.0043 -0.004 ± 0.021 NS NS 
 the COPD with asthma-like features group (baseline vs two years later: 0.77 ± 0.22% vs 0.70 ± 0.21%, 
P = 0.0148). The annual changes in %CSA<5 were significantly different between the two groups 
(COPD vs asthma-like features: 0.051 ± 0.104 vs -0.035 ± 0.094, P=0.0007).On the other hand, the 
mean WA% at the distal bronchi significantly decreased in the COPD group (baseline vs two years 
later: 83.9 ± 3.2% vs 82.0 ± 4.6%, P = 0.0043), while the WA% in the COPD with asthma-like features 
group did not significantly change during the follow-up period (baseline vs two years later: 83.9 ± 3.5% 
vs 83.2 ± 4.0%, not significant). The annual changes in mean fifth WA% were not significantly different 
between the two groups (COPD vs asthma-like features: -0.011 ± 0.025 vs -0.004 ± 0.021, P = 0.1352). 
 
 
Fig 2. Changes in radiological parameters over two years of follow-up 
Notes: Radiological parameters were compared between enrollment and two-year follow-up with the 
Wilcoxon signed-rank test. WA% shows the mean wall area percentage at the 5th generation of bronchi. 
Abbreviations: ALF, asthma-like features; LAA, low-attenuation area; CSA<5, the cross-sectional area 
of pulmonary vessels < 5 mm
2
; WA%, wall area percentage; NS, not significant 
 
Discussion 
This is the first report of longitudinal morphological changes, including parameters of 
emphysema, airway wall thickness, and vascularity, in COPD with asthma-like features. The key 
findings of our study were as follows. First, emphysematous features (LAA%) significantly increased in 
both groups. Second, longitudinal changes in the percentage of small pulmonary vessels (%CSA<5) 
differed between COPD with asthma-like features and COPD alone. Among patients with COPD with 
asthma-like features, %CSA<5 significantly decreased during the two years of follow-up. In 
contrast, %CSA<5 significantly increased in patients with COPD alone. Third, we observed a slight but 
significant decrease in WA% in patients with COPD alone, although there was no significant change in 
WA% in patients with COPD with asthma-like features during the study period. 
LAA% is recognized as an index of the extent of emphysema [12]. Emphysema is the main 
pathological lesion in COPD and is usually caused by tobacco smoke [1]. It is well known that LAA% 
gradually increases over time in COPD patients [30]. Patients with ACO have less severe emphysema 
 than patients with COPD alone [25, 31]. Although there are a few reports on the cross-sectional 
structural characteristics of ACO [8, 32], longitudinal emphysematous changes in ACO have not been 
reported. Our findings suggest that emphysema progresses similarly in patients with COPD and those 
with COPD with asthma-like features. In COPD, exposure to tobacco smoke leads to chronic airway 
inflammation through the activation of inflammatory cells [33]. Regardless of smoking cessation, 
chronic inflammation persists [34] and causes emphysema progression [21]. In our study, most patients 
were past smokers, and all had a significant smoking history. Therefore, our data indicates that 
emphysematous destruction may progress in both patients with COPD and those with COPD with 
asthma-like features due to the fact that airway inflammation persist even after smoking cessation. 
Another novel finding of this study was that changes in %CSA<5 differed between patients 
with COPD alone and those with asthma-like features. The %CSA<5 is a novel CT marker for 
microvascular alteration, and it is negatively correlated with the extent of emphysema and airflow 
limitation in COPD [18]. However, Saruya et al. reported that the progression of emphysema and 
pulmonary vascular alteration do not always occur in parallel. They found that, although emphysema 
might progress, the %CSA<5 might not always decrease, and the change in decrease was associated 
with various patient improvements, such as smoking cessation, decreased exacerbation risk, and 
appropriate medical treatment [24]. We previously reported that %CSA<5 was higher in patients with 
ACO than in patients with COPD and inhaled corticosteroid (ICS)/long acting beta-agonist (LABA) 
treatment decreased %CSA<5 over 3 months in the ACO patients [35]. Vascular endothelial growth 
factor (VEGF) has an important role for the pathogenesis of several lung diseases [36]. In COPD, 
VEGF and VEGF receptor 2 are decreased, which causes the destruction of alveolar walls (emphysema) 
and loss of pulmonary microvessels [37]. On the contrary, airway inflammation occurs in response to 
increased secretion of VEGF in asthma, which leads to abnormal vascularity and increased vessel size 
[38]. These difference in microvessels might lead to the difference in change of %CSA<5 we observed. 
Regarding the response to treatment, although previous studies reported that patients with ACO have a 
worse clinical course than patients with COPD alone [32, 39], recent studies have found that patients 
with ACO have a better prognosis [8, 9]. Suzuki et al. demonstrated that appropriate treatment 
improved the clinical course of patients with COPD with asthma-like features due to a better response 
to treatment [9]. Furthermore, Cosio et al. found that patients with ACO had a better 1-year prognosis 
 than patients with COPD alone [8]. Therefore, various patient factors may affect the changes 
in %CSA<5 observed in both groups. 
There was a significant decrease in WA% within patients with COPD alone, but with COPD 
with asthma-like features there was no significant change in WA% throughout the study period. Several 
transitional studies found that more airway wall thickening occurs in asthma than in COPD or controls 
[40, 41]. Patients with ACO had significantly greater wall thickening than those with COPD alone [25]. 
In addition, respiratory medications such as ICS and bronchodilators decreased airway wall thickening 
in both asthma and COPD [42, 43]. We previously demonstrated that the changes of airway wall 
thickness in patients with COPD alone may be associated to smoking cessation and appropriate 
treatment [26]. In this longitudinal study, the COPD patients with asthma-like features were more likely 
to have a severe GOLD stage at enrollment. Several previous reports also found that patients with ACO 
had lower FEV1% at enrollment [39, 44]. We propose that more severe GOLD stage and greater airway 
remodeling were associated with the lesser change in WA% in patients with COPD with asthma-like 
features. 
Another reason for no significant change in WA% among patients with COPD with asthma-like 
features may be that they had fewer features of asthma by our criteria compared to the criteria for ACO 
[5]. In the present study, 13 patients (48%) with COPD with asthma-like features had only one or two 
features of asthma. However, in a large cohort study (the COPD History Assessment in Spain (CHAIN) 
study), the diagnostic criteria required for ACO was one major criterion (bronchodilator test >400 mL 
and 15% and past medical history of asthma) or two minor criteria (blood eosinophils > 5%, IgE > 100 
IU/mL, or two separate bronchodilator tests > 200 mL and 12%) [8]. We consider that the number of 
asthma-like features possibly may be associated with a decrease in WA% due to response to treatment. 
Although there are few randomized clinical studies to provide guidance for the treatment of 
ACO, treatment with ICS is recommended for patients with ACO, like as for patients with asthma [5]. 
Recently, GOLD guideline recommends the treatment containing ICS for patients with high eosinophil 
counts in COPD [45]. In this study, the rate of ICS (including ICS/LABA) use was increased during the 
follow-up period. About 75 percent of patients with COPD with asthma-like features used ICS and 
ICS/LABA 2 years later. These findings support the strategy of considering treatment with ICS in 
patients with COPD with asthma-like features, even if they have not been already diagnosed with ACO 
 [8, 9]. 
 
Limitations 
Our study has several limitations. First, the study only enrolled a small number of patients and 
was a preliminary and exploratory investigation conducted at a single institute. Second, the 
observational period of two years was relatively short. Third, because of the small number of subjects 
we could not evaluate each CT parameter for differences in treatment, with or without ICS, rate of 
smoking cessation, and frequency of exacerbations. Further prospective studies with larger study 
populations and longer observational period are required to confirm these results.  
 
Conclusions 
In conclusion, emphysematous regions (LAA%) increased over time in patients with COPD 
with and without asthma-like features. The %CSA<5 and the WA% at the distal bronchi did not change 
in parallel with LAA in either group. Furthermore, the change in %CSA<5 over time in COPD with 
asthma- like features was significantly different than in COPD alone. Patients with COPD with 
asthma-like features may have different longitudinal structural changes compared to those observed in 
COPD patients. 
  
 Acknowledgments 
We thank Dr. Toshio Suzuki, Dr. Akira Nishiyama, Mrs. Chieko Handa, Mrs. Tamie Hirano, 
and Miki Sakurai for their technical assistance and general support. We also wish to thank Dr. Shunsuke 
Furuta and Dr. Yuki Shiko for advice on the statistical analyses. 
  
 References 
1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global 
Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 
Report: GOLD Executive Summary. Eur Respir J. 2017;49(3). doi: 10.1183/13993003.00214-2017. 
PubMed PMID: 28182564. 
2. The top 10 causes of death, World Health Organization 2017. Available from: 
http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. 
3. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. 
American Thoracic Society. Am J Respir Crit Care Med. 1995;152(5 Pt 2):S77-121. PubMed PMID: 
7582322. 
4. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility 
to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-38. doi: 
10.1056/NEJMoa0909883. PubMed PMID: 20843247. 
5. Asthma COPD and Ashtma-COPD Overlap Syndrome (ACOS). Global Initiative for Asthma 
and Global Initiative for Chronic Obstructive Lung Disease 2015. Available from: 
https://goldcopd.org/asthma-copd-asthma-copd-overlap-syndrome/. 
6. Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): A diagnostic 
challenge. Respirology. 2016;21(3):410-8. doi: 10.1111/resp.12653. PubMed PMID: 26450153. 
7. Soler-Cataluna JJ, Cosio B, Izquierdo JL, Lopez-Campos JL, Marin JM, Aguero R, et al. 
Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 
2012;48(9):331-7. doi: 10.1016/j.arbres.2011.12.009. PubMed PMID: 22341911. 
8. Cosio BG, Soriano JB, Lopez-Campos JL, Calle-Rubio M, Soler-Cataluna JJ, de-Torres JP, et 
al. Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest. 2016;149(1):45-52. doi: 
10.1378/chest.15-1055. PubMed PMID: 26291753. 
9. Suzuki M, Makita H, Konno S, Shimizu K, Kimura H, Kimura H, et al. Asthma-like Features 
and Clinical Course of Chronic Obstructive Pulmonary Disease. An Analysis from the Hokkaido COPD 
Cohort Study. Am J Respir Crit Care Med. 2016;194(11):1358-65. doi: 10.1164/rccm.201602-0353OC. 
PubMed PMID: 27224255. 
10. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: 
predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964-71. 
doi: 10.1183/09031936.06.00072105. PubMed PMID: 16446316. 
11. Fattahi F, ten Hacken NH, Lofdahl CG, Hylkema MN, Timens W, Postma DS, et al. Atopy is a 
risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study. Respir Res. 
2013;14:10. doi: 10.1186/1465-9921-14-10. PubMed PMID: 23356508; PubMed Central PMCID: 
PMCPMC3599617. 
12. Gevenois PA, de Maertelaer V, De Vuyst P, Zanen J, Yernault JC. Comparison of computed 
density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med. 
1995;152(2):653-7. doi: 10.1164/ajrccm.152.2.7633722. PubMed PMID: 7633722. 
 13. Mishima M, Hirai T, Itoh H, Nakano Y, Sakai H, Muro S, et al. Complexity of terminal 
airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic 
obstructive pulmonary disease. Proc Natl Acad Sci U S A. 1999;96(16):8829-34. PubMed PMID: 
10430855; PubMed Central PMCID: PMCPMC17692. 
14. Haruna A, Muro S, Nakano Y, Ohara T, Hoshino Y, Ogawa E, et al. CT scan findings of 
emphysema predict mortality in COPD. Chest. 2010;138(3):635-40. doi: 10.1378/chest.09-2836. 
PubMed PMID: 20382712. 
15. Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, et al. Computed tomographic 
measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J 
Respir Crit Care Med. 2000;162(3 Pt 1):1102-8. doi: 10.1164/ajrccm.162.3.9907120. PubMed PMID: 
10988137. 
16. Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S, et al. Airflow limitation 
and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 
2006;173(12):1309-15. doi: 10.1164/rccm.200601-037OC. PubMed PMID: 16556695. 
17. Xie X, Dijkstra AE, Vonk JM, Oudkerk M, Vliegenthart R, Groen HJ. Chronic respiratory 
symptoms associated with airway wall thickening measured by thin-slice low-dose CT. AJR Am J 
Roentgenol. 2014;203(4):W383-90. doi: 10.2214/AJR.13.11536. PubMed PMID: 25247967. 
18. Matsuoka S, Washko GR, Dransfield MT, Yamashiro T, San Jose Estepar R, Diaz A, et al. 
Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations 
with emphysema and airflow limitation. Acad Radiol. 2010;17(1):93-9. doi: 10.1016/j.acra.2009.07.022. 
PubMed PMID: 19796970; PubMed Central PMCID: PMCPMC2790546. 
19. Matsuoka S, Washko GR, Yamashiro T, Estepar RS, Diaz A, Silverman EK, et al. Pulmonary 
hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. 
Am J Respir Crit Care Med. 2010;181(3):218-25. doi: 10.1164/rccm.200908-1189OC. PubMed PMID: 
19875683; PubMed Central PMCID: PMCPMC2817812. 
20. Jones PW, Anderson JA, Calverley PM, Celli BR, Ferguson GT, Jenkins C, et al. Health status 
in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res. 
2011;12:71. doi: 10.1186/1465-9921-12-71. PubMed PMID: 21627828; PubMed Central PMCID: 
PMCPMC3117702. 
21. Soejima K, Yamaguchi K, Kohda E, Takeshita K, Ito Y, Mastubara H, et al. Longitudinal 
follow-up study of smoking-induced lung density changes by high-resolution computed tomography. 
Am J Respir Crit Care Med. 2000;161(4 Pt 1):1264-73. doi: 10.1164/ajrccm.161.4.9905040. PubMed 
PMID: 10764322. 
22. Tanabe N, Muro S, Hirai T, Oguma T, Terada K, Marumo S, et al. Impact of exacerbations on 
emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 
2011;183(12):1653-9. doi: 10.1164/rccm.201009-1535OC. PubMed PMID: 21471102. 
23. Ohara T, Hirai T, Sato S, Terada K, Kinose D, Haruna A, et al. Longitudinal study of airway 
dimensions in chronic obstructive pulmonary disease using computed tomography. Respirology. 
2008;13(3):372-8. doi: 10.1111/j.1440-1843.2008.01269.x. PubMed PMID: 18399859. 
 24. Saruya S, Matsuoka S, Yamashiro T, Matsushita S, Fujikawa A, Yagihashi K, et al. 
Quantitative CT measurements of small pulmonary vessels in chronic obstructive pulmonary disease: 
do they change on follow-up scans? Clin Physiol Funct Imaging. 2016;36(3):211-7. doi: 
10.1111/cpf.12215. PubMed PMID: 25393655. 
25. Hardin M, Cho M, McDonald ML, Beaty T, Ramsdell J, Bhatt S, et al. The clinical and 
genetic features of COPD-asthma overlap syndrome. Eur Respir J. 2014;44(2):341-50. doi: 
10.1183/09031936.00216013. PubMed PMID: 24876173; PubMed Central PMCID: 
PMCPMC4154588. 
26. Takayanagi S, Kawata N, Tada Y, Ikari J, Matsuura Y, Matsuoka S, et al. Longitudinal changes 
in structural abnormalities using MDCT in COPD: do the CT measurements of airway wall thickness 
and small pulmonary vessels change in parallel with emphysematous progression? Int J Chron Obstruct 
Pulmon Dis. 2017;12:551-60. doi: 10.2147/COPD.S121405. PubMed PMID: 28243075; PubMed 
Central PMCID: PMCPMC5315203. 
27. Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with 
COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-46. PubMed PMID: 
15219010. 
28. Committee of Pulmonary Physiology, The Japanese Respiratory Society, Guidelines for 
pulmonary function tests: spirometry, flow-volume curve, diffusion capacity of the lung. 1st ed. Nihon 
Kokyuki Gakkai Zasshi. 2004;(Suppl):1-56. 
29. Yamashiro T, Matsuoka S, Estepar RS, Dransfield MT, Diaz A, Reilly JJ, et al. Quantitative 
assessment of bronchial wall attenuation with thin-section CT: An indicator of airflow limitation in 
chronic obstructive pulmonary disease. AJR Am J Roentgenol. 2010;195(2):363-9. doi: 
10.2214/AJR.09.3653. PubMed PMID: 20651191. 
30. Tanabe N, Muro S, Sato S, Tanaka S, Oguma T, Kiyokawa H, et al. Longitudinal study of 
spatially heterogeneous emphysema progression in current smokers with chronic obstructive pulmonary 
disease. PLoS One. 2012;7(9):e44993. doi: 10.1371/journal.pone.0044993. PubMed PMID: 23028728; 
PubMed Central PMCID: PMCPMC3445600. 
31. Kitaguchi Y, Yasuo M, Hanaoka M. Comparison of pulmonary function in patients with 
COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation. Int J Chron Obstruct 
Pulmon Dis. 2016;11:991-7. doi: 10.2147/COPD.S105988. PubMed PMID: 27274220; PubMed Central 
PMCID: PMCPMC4869610. 
32. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, et al. The clinical 
features of the overlap between COPD and asthma. Respir Res. 2011;12:127. doi: 
10.1186/1465-9921-12-127. PubMed PMID: 21951550; PubMed Central PMCID: PMCPMC3204243. 
33. Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive 
pulmonary disease. Proc Am Thorac Soc. 2009;6(6):524-6. doi: 10.1513/pats.200904-016DS. PubMed 
PMID: 19741261. 
34. Ind PW. COPD disease progression and airway inflammation: uncoupled by smoking 
cessation. Eur Respir J. 2005;26(5):764-6. doi: 10.1183/09031936.05.00102805. PubMed PMID: 
 16264034. 
35. Suzuki T, Tada Y, Kawata N, Matsuura Y, Ikari J, Kasahara Y, et al. Clinical, physiological, 
and radiological features of asthma-chronic obstructive pulmonary disease overlap syndrome. Int J 
Chron Obstruct Pulmon Dis. 2015;10:947-54. doi: 10.2147/COPD.S80022. PubMed PMID: 26028967; 
PubMed Central PMCID: PMCPMC4440433. 
36. Kanazawa H. Role of vascular endothelial growth factor in the pathogenesis of chronic 
obstructive pulmonary disease. Med Sci Monit. 2007;13(11):RA189-95. PubMed PMID: 17968307. 
37. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death 
and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor 
receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163(3 Pt 1):737-44. doi: 
10.1164/ajrccm.163.3.2002117. PubMed PMID: 11254533. 
38. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir 
Crit Care Med. 1997;156(1):229-33. doi: 10.1164/ajrccm.156.1.9607066. PubMed PMID: 9230753. 
39. Menezes AMB, Montes de Oca M, Perez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela 
MV, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: 
COPD-asthma. Chest. 2014;145(2):297-304. doi: 10.1378/chest.13-0622. PubMed PMID: 24114498. 
40. Shimizu K, Hasegawa M, Makita H, Nasuhara Y, Konno S, Nishimura M. Comparison of 
airway remodelling assessed by computed tomography in asthma and COPD. Respir Med. 
2011;105(9):1275-83. doi: 10.1016/j.rmed.2011.04.007. PubMed PMID: 21646007. 
41. Kosciuch J, Krenke R, Gorska K, Zukowska M, Maskey-Warzechowska M, Chazan R. 
Airway dimensions in asthma and COPD in high resolution computed tomography: can we see the 
difference? Respir Care. 2013;58(8):1335-42. doi: 10.4187/respcare.02175. PubMed PMID: 23307823. 
42. Niimi A, Matsumoto H, Amitani R, Nakano Y, Sakai H, Takemura M, et al. Effect of 
short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Am J Med. 
2004;116(11):725-31. doi: 10.1016/j.amjmed.2003.11.026. PubMed PMID: 15144908. 
43. Hasegawa M, Makita H, Nasuhara Y, Odajima N, Nagai K, Ito Y, et al. Relationship between 
improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in 
COPD. Thorax. 2009;64(4):332-8. doi: 10.1136/thx.2008.103671. PubMed PMID: 19074932. 
44. Baarnes CB, Kjeldgaard P, Nielsen M, Miravitlles M, Ulrik CS. Identifying possible 
asthma-COPD overlap syndrome in patients with a new diagnosis of COPD in primary care. NPJ Prim 
Care Respir Med. 2017;27:16084. doi: 10.1038/npjpcrm.2016.84. PubMed PMID: 28055002; PubMed 
Central PMCID: PMCPMC5214698. 
45. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive 
Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease 2019. Available from: 
https://goldcopd.org/gold-reports/. 
 
 
 Fig 1. Flow chart of the study participants 
 
  
 Fig 2. Changes in radiological parameters over two years of follow-up 
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